Investors seeking international diversification often face a choice between a broad total-market approach and a targeted factor strategy. That is precisely the distinction between VXUS and IQLT. Although both funds provide non-U.S. equity exposure, they are not direct substitutes: VXUS is a low-cost, all-cap, developed-and-emerging market index fund, while IQLT is a developed-market, quality-screened fund that tilts toward companies with high return on equity, stable earnings, and modest debt. Comparing them clarifies how an investor might prioritize broad diversification versus factor-based quality, cost efficiency, and defensive characteristics.
IQLT is a passively managed factor ETF that tracks the MSCI World ex USA Sector Neutral Quality Index. It selects and weights large- and mid-capitalization stocks from developed markets outside the United States based on three quality metrics: return on equity, earnings variability, and debt-to-equity. The sector-neutral design keeps its sector weights broadly aligned with the parent index while concentrating on higher-quality names within each sector. IQLT holds roughly 325 securities and carries a 0.30% expense ratio. I also checked this using Tickeron’s AI Screener to see how the fund’s holdings compare to peers in the international equity space.
Top holdings are dominated by established multinationals such as ASML (about 6%), Allianz, Novartis, AstraZeneca, Roche, ABB, Nestlé, Zurich Insurance, and Shell. Financials are the largest sector at roughly 26%, followed by industrials (about 17%) and technology (about 11%). The fund rebalances periodically to maintain its quality and sector-neutral characteristics.
VXUS is a passively managed, market-capitalization-weighted index fund that tracks the FTSE Global All Cap ex US Index, covering developed and emerging markets outside the United States. With approximately 8,800 holdings spanning large-, mid-, and small-cap stocks, it represents roughly 99% of global market capitalization outside the U.S. Its 0.05% expense ratio is among the lowest in international equity investing.
Top positions include Taiwan Semiconductor Manufacturing, Samsung Electronics, SK Hynix, ASML, Tencent, HSBC, Roche, Shell, Royal Bank of Canada, and Novartis. Sector exposure is led by financials (about 23%) and technology (about 21%), with industrials at roughly 15%. Unlike IQLT, VXUS includes meaningful emerging-market exposure — Taiwan, South Korea, China, and India feature prominently — and pays quarterly distributions.
Both funds operate within the broader international equity landscape, where several forces are shaping relative performance. A weaker U.S. dollar has historically supported non-U.S. earnings, while persistent valuation discounts in international markets relative to U.S. equities have renewed interest in overseas diversification. The global semiconductor cycle, driven by artificial intelligence demand, has favored technology-heavy markets such as Taiwan and South Korea — a tailwind more directly captured by VXUS. Meanwhile, elevated interest rates have rewarded companies with strong balance sheets and consistent profitability, reinforcing the quality factor underpinning IQLT. Geopolitical tensions, currency fluctuations, and China's uneven economic recovery remain key risks that affect the two funds asymmetrically given VXUS's emerging-market footprint.
In recent market cycles, IQLT's quality tilt has generally produced more resilient relative performance during risk-off episodes, reflecting its focus on profitable, lower-leverage companies. VXUS, by contrast, has benefited from broader participation across technology and emerging markets, particularly as semiconductor and Asian equity strength lifted its largest holdings. IQLT carries a lower five-year beta of roughly 0.85 versus a beta closer to 1.0 for VXUS, indicating comparatively lower volatility. However, VXUS's substantially lower cost and greater diversification have historically made it a favored core holding. In terms of relative positioning, IQLT offers defensive, quality-driven exposure with less emerging-market sensitivity, while VXUS provides maximum breadth and lower fees at the expense of greater cyclical and geographic variability. From what I see, this distinction matters most when constructing a portfolio for different risk tolerances.
In my own analysis of international ETFs like these, I often turn to Tickeron’s AI Screener to quickly compare holdings, sector weights, and volatility metrics across similar funds. It helps surface how quality screens stack up against broad-market exposure without manually sifting through thousands of data points. This kind of tool fits naturally into reviewing structural differences before making allocation decisions.
Based on observable structural and trend characteristics, Tickeron's AI would likely favor IQLT in the current environment. The fund's quality factor construction emphasizes companies with high return on equity, stable earnings, and lower debt — attributes that have historically provided downside resilience and more consistent trend behavior during periods of macro uncertainty. Its lower beta and sector-neutral quality tilt offer a comparatively defensive profile, and recent quality-factor leadership supports its relative positioning. VXUS retains clear advantages in cost efficiency and diversification breadth, but its emerging-market and small-cap exposure introduces greater cyclical volatility. On balance, the AI leans toward IQLT for investors prioritizing risk-adjusted quality exposure over maximum breadth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for VXUS turned positive on October 28, 2026. Looking at past instances where VXUS's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 63 cases where VXUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +1.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where VXUS advanced for three days, in 279 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VXUS as a result. In 65 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
VXUS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VXUS crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VXUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for VXUS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Category ForeignLargeBlend